PSGL-1 has been identified as a negative checkpoint of CD4+ T-cells35, and the role of CD4+ T-cells as a key contributor to immunotherapy efficacy and tumor immunity was recently reported50–52. The gene discussed is CD4; the disease is neoplasm.